Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism

Beal offered his groupʼs most recent findings on mitochondrial dysfunction and neurodegenerative diseases, specifically involving animal models of Parkinsonʼs and Huntingtonʼs disease to compare Ubiquinol and conventional CoQ10.

In one of the animal models, they utilized a neurotoxin called MPTP, which induces effects in the brain that are analogous to clinical and biochemical changes seen in patients with Parkinsonʼs disease. The rodents treated with CoQ10 (both Ubiquinone and Ubiquinol forms) had significantly less formation of alpha synuclein aggregates, which is a major pathological hallmark found in Parkinsonʼs disease patients. Additionally, the scientists noted that the Ubiquinol form resulted in higher plasma levels and exerted a greater neuroprotective effect against the damaging effect of MPTP.

Journal: Journal of Neurochemistry

Authors: Cleren C, Yang L, Lorenzo B, Calingasan NY, SchomerA, Sireci A, Wille EJ, Beal MF

Department: Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, New York 10021, USA

Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/17973981

Contact